Coya Therapeutics Q2 EPS $(0.31) Up From $(1.32) YoY; Cash And Cash Equivalents Of $13.1M
Portfolio Pulse from Benzinga Newsdesk
Coya Therapeutics reported Q2 losses of $(0.31) per share, a 76.52% increase over losses of $(1.32) per share from the same period last year. The company also reported cash and cash equivalents of $13.1M.
August 08, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Coya Therapeutics reported a smaller loss in Q2 compared to the same period last year, which could be seen as a positive sign. However, the company is still operating at a loss.
While the reduction in losses could be seen as a positive sign, the fact that the company is still operating at a loss may temper investor enthusiasm. The company's cash position is also a key factor to consider.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100